Stifel Nicolaus started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The firm issued a buy rating and a $35.00 price objective on the stock.
Rapport Therapeutics Stock Down 6.8 %
Shares of RAPP opened at $23.30 on Tuesday. Rapport Therapeutics has a 1-year low of $18.00 and a 1-year high of $27.11.
Insider Buying and Selling at Rapport Therapeutics
In related news, Director James Healy acquired 44,032 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were purchased at an average cost of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the acquisition, the director now directly owns 40,851 shares in the company, valued at $1,001,666.52. The purchase was disclosed in a filing with the SEC, which is available at this link.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- How to Buy Cheap Stocks Step by Step
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- How to Invest in the FAANG Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Financial Services Stocks Investing
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
